586410-15-3Relevant academic research and scientific papers
Discovery of efficient stimulators for adult hippocampal neurogenesis based on scaffolds in dragon's blood
Liang, Jian-Hua,Yang, Liang,Wu, Si,Liu, Si-Si,Cushman, Mark,Tian, Jing,Li, Nuo-Min,Yang, Qing-Hu,Zhang, He-Ao,Qiu, Yun-Jie,Xiang, Lin,Ma, Cong-Xuan,Li, Xue-Meng,Qing, Hong
, p. 382 - 392 (2017/05/19)
Reduction of hippocampal neurogenesis caused by aging and neurological disorders would impair neural circuits and result in memory loss. A new lead compound (N-trans-3′,4'-methylenedioxystilben-4-yl acetamide 27) has been discovered to efficiently stimulate adult rats' neurogenesis. In-depth structure-activity relationship studies proved the necessity of a stilbene scaffold that is absent in highly cytotoxic analogs such as chalcones and heteroaryl rings and inactive analogs such as diphenyl acetylene and diphenyl ethane, and validated the importance of an NH in the carboxamide and a methylenedioxy substituent on the benzene ring. Immunohistochemical staining and biochemical analysis indicate, in contrast to previously reported neuroprotective chemicals, N-stilbenyl carboxamides have extra capacity for neuroproliferation-type neurogenesis, thereby providing a foundation for improving the plasticity of the adult mammalian brain.
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFRT790M mutant
Song, Anran,Zhang, Jianbin,Ge, Yang,Wang, Changyuan,Meng, Qiang,Tang, Zeyao,Peng, Jinyong,Liu, Kexin,Li, Yanxia,Ma, Xiaodong
, p. 2724 - 2729 (2017/04/17)
With the aim to overcome the drug resistance induced by the EGFR T790M mutation (EGFRT790M), herein, a family of diphenylpyrimidine derivatives (Sty-DPPYs) bearing a C-2 (E)-4-(styryl)aniline functionality were designed and synthesized as potential EGFRT790M inhibitors. Among them, the compound 10e displayed strong potency against the EGFRT790M enzyme, with the IC50 of 11.0?nM. Compound 10e also showed a higher SI value (SI?=?49.0) than rociletinib (SI?=?21.4), indicating its less side effect. In addition, compound 10e could effectively inhibit the proliferation of H1975 cells harboring the EGFRT790M mutation, within the concentration of 2.91?μM. Significantly, compound 10e has low toxicity against the normal HBE cell (IC50?=?22.48?μM). This work provided new insights into the discovery of potent and selective inhibitor against EGFRT790M over wild-type (EGFRWT).
Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
Je?ábek, Jakub,Uliassi, Elisa,Guidotti, Laura,Korábe?ny, Jan,Soukup, Ond?ej,Sepsova, Vendula,Hrabinova, Martina,Ku?a, Kamil,Bartolini, Manuela,Pe?a-Altamira, Luis Emiliano,Petralla, Sabrina,Monti, Barbara,Roberti, Marinella,Bolognesi, Maria Laura
, p. 250 - 262 (2017/01/10)
Multi-target drug discovery is one of the most followed approaches in the active central nervous system (CNS) therapeutic area, especially in the search for new drugs against Alzheimer's disease (AD). This is because innovative multi-target-directed ligands (MTDLs) could more adequately address the complexity of this pathological condition. In a continuation of our efforts aimed at a new series of anti-AD MTDLs, we combined the structural features of the cholinesterase inhibitor drug tacrine with that of resveratrol, which is known for its purported antioxidant and anti-neuroinflammatory activities. The most interesting hybrid compounds (5, 8, 9 and 12) inhibited human acetylcholinesterase at micromolar concentrations and effectively modulated Aβ self-aggregation in?vitro. In addition, 12 showed intriguing anti-inflammatory and immuno-modulatory properties in neuronal and glial AD cell models. Importantly, the MTDL profile is accompanied by high-predicted blood-brain barrier permeability, and low cytotoxicity on primary neurons.
Novel stilbene derivative and preparation method thereof
-
, (2017/04/22)
The invention provides a novel stilbene derivative. The novel stilbene derivative is a compound with a general formula I or II as described in the specification or a salt formed by the compound with the general formula I or II as described in the specification and inorganic acid or organic acid. In the general formula I or II, X represents a hydrogen atom or halogen atom; R represents a substituent selected from a group consisting of C1-5 alkyl groups, C2-4 alkenyl groups, C2-4 alkynyl groups, C3-6 cycloalkyl groups, five-to-twelve-component aryl groups, two-to-five-component heteralkyl groups, three-to-six-component hetercycloalkyl groups, five-to-twelve-component heteraryl groups, substituted three-to-six-component cycloalkanes, substituted five-to-twelve-component aryl groups and substituted five-to-twelve-component heteralkyl groups; or the substituent represented by R is a first substituent formed by a spacer group and any one selected from a group consisting of C3-6 cycloalkanes, three-to-six-component hetercycloalkanes, five-to-twelve-component aryl groups and five-to-twelve-component heteraryl groups, and the spacer group comprises -CH2-, -(CH2)2-, -CH=CH-, -CH2O-, -CH(OCH3)- and -CH2S-.
Synthesis and biological evaluation of novel resveratrol-oxadiazole hybrid heterocycles as potential antiproliferative agents
Murty,Penthala, Raju,Polepalli, Sowjanya,Jain
, p. 627 - 643 (2016/03/08)
A novel class of resveratrol-oxadiazole hybrid compounds was synthesized to screen for their in vitro antiproliferative activity against three human cancer cell lines. All the compounds showed superior antiproliferative activity than the reference compound resveratrol. The most promising active compounds in this series were 1g, 2g, 1c, 2c, 2i and 1a (GI50 0.1 μM), endowed with excellent antiproliferative activity. Thus, we believe that resveratrol-oxadiazole hybrid compounds may possibly be used as a good leads for the development of new antiproliferative agents. Structures of newly synthesized compounds were confirmed by NMR and IR spectral data.
Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein
Li, Shanshan,Zhang, Wenda,Yang, Yanwei,Ma, Ting,Guo, Jianpeng,Wang, Shanshan,Yu, Wenying,Kong, Lingyi
, p. 1006 - 1018 (2016/11/09)
Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target. Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers. To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biological reactions of STAT3 to our knowledge. Most of these compounds were demonstrated with preferential antitumor activity with low IC50values against two cancer cell lines. Particularly, compound 7d was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid. Meanwhile, the novel derivatives significantly inhibited the proliferation and induced the apoptosis of tumor cells. Molecular docking further disclosed the binding modes of STAT3 with the inhibitors. In addition, compound 7d orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo, indicating its great potential as an efficacious drug candidate for human cancer therapy.
Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents
Yan, Jun,Guo, Yueyan,Wang, Yali,Mao, Fei,Huang, Ling,Li, Xingshu
, p. 220 - 229 (2015/03/31)
To identify novel multi-target-directed drug candidates for the treatment of cancer, a series of benzoselenazole-stilbene hybrids were synthesised by combining the pharmacophores of resveratrol and ebselen. The biological assay indicated that all of the h
Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease
Lu, Chuanjun,Guo, Yueyan,Yan, Jun,Luo, Zonghua,Luo, Hai-Bin,Yan, Ming,Huang, Ling,Li, Xingshu
, p. 5843 - 5859 (2013/08/23)
A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer's disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced β-amyloid (Aβ)
Direct amination of phenols under metal-free conditions
Yu, Jianzhong,Wang, Yongtao,Zhang, Peizhi,Wu, Jun
supporting information, p. 1448 - 1454 (2013/07/26)
Herein, we disclose the metal-free synthesis of arylamines via the direct amination of phenols using aminating reagents. This reaction procedure uses easy accessible aminating reagents and provides a versatile synthetic route to a broad range of arylamines with various functionalities in good to excellent yield. By using a two-step route of amination and oxidative coupling reaction, we synthesized three naturally occurring carbazole alkaloids: murrayafoline A, mukonine, and clausenine from two commercially available phenols. Georg Thieme Verlag Stuttgart · New York.
NOVEL STILBENE ANALOGS
-
Page/Page column 19, (2010/05/13)
The present invention relates to Stilbene derivatives of the general formula I or a pharmaceutically acceptable salt thereof have properties such as high water solubility, bioavailability and effective as carcinostatics.
